Alzheimers Stocks - Alzheimers Stocks to Buy

Home
Stocks to Watch
Top Stocks 2018
Penny Stocks
Stock Picks
Stock Gainers - Hot Stocks
Stock Losers - Bad Stocks
Best Performing Stocks
2017 IPO's
Stocks 2017
Top Stocks 2017
Top Penny Stocks 2017
Best Marijuana Stocks
Best Oil Stocks
Best Gold Stocks
Best Uranium Stocks
Best China Stocks
Best Coffee Stocks
Cramer Stock Picks
Penny Stocks to Buy
Cheap Stocks 2017
Top 10 Stocks
Top 10 Penny Stocks
Long Term Stocks
Dividend Stocks
How to Day Trade
Stock Trading Rules
Site Map

Alzheimer's Stocks - Best Alzheimer's Stocks

Alzheimer's stocks are getting some play and are probably worth a buy in 2015.  From Alzheimer's Penny Stocks to Regular Alzheimer's Stocks, below is a list of some Top Alzheimer's Stocks to do your research on.  Alzheimer's is expected to triple by 2045 and several companies are working on key drugs to try and solve the epidemic.   While these Alzheimer's stocks are risky, they could offer a nice way to diversify your portfolio.

Alzheimer’s disease is a progressive, neurodegenerative disorder characterized by problems with memory, thinking and behavior that eventually become severe enough to affect daily tasks. An estimated 5.3 million people in the United States are currently living with Alzheimer’s disease. Alzheimer’s disease is the fifth leading cause of death in the United States among those aged 65 and older and will be the underlying cause of death for more than 500,000 Americans in 2015.

If you are looking for some hot stocks, check out my biggest gainers page, my top penny stock gainers page, and my top stock gainers page.  I also have updates on my stock blog.  If you want to learn about day trading, go to my day trading page.

counter create hit

Top Alzheimer's Stocks - Avanir Pharmaceuticals (AVNR) - AVNR was my top Alzheimer's Disease stock last year but they were bought out for $17 for share.  Now, a company called Concert Pharmaceuticals (CNCE) has partned with Avanir and said this during the last conference call.

Avanir Pharmaceuticals intends to meet with the U.S. Food and Drug Administration in early 2015 to discuss the potential advancement of AVP-786 into Phase 3 clinical testing for the treatment of agitation in patients with Alzheimer’s Disease. In addition, Avanir is conducting a Phase 2 clinical trial evaluating AVP-786 for the treatment of major depressive disorder.  
Highlighted broad clinical potential of AVP-786 under collaboration with Avanir Pharmaceuticals.

Concert Pharmaceuticals (CNCE) is now one of the best positioned Alheimer's stocks going forward and shares have corrected to $15 from $18.  Watch CNCE in 2015.

Best Alzheimer's Stocks 2015 - Acadia Pharmaceuticals (ACAD) has been one of the one of the best drugs stocks over the last few years and the company has a drug to potentially treat Alzheimer's. 

Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial in schizophrenia. These may include treatment for psychoses associated with other neurological disorders, including Alzheimer's disease. 

The FDA has not approved any drug to treat ADP. As symptoms progress and become more severe, physicians often resort to off-label use of antipsychotic medications in ADP patients. Current antipsychotic drugs are associated with a number of side effects, which can be problematic for elderly patients with Alzheimer's disease. In addition, antipsychotic drugs may exacerbate the cognitive disturbances associated with Alzheimer's disease. Current antipsychotic drugs also have a black box warning for use in elderly patients with dementia-related psychosis due to increased mortality and morbidity.

Alzheimers Stocks to Buy - Activis (ACT)/Forest Laboratories Inc. (FRX) - Forest Laboratories Inc. (FRX) has an Alzheimers drug called Namenda which is designed to treat moderate to severe cases of Alzheimers.  The stock surged last year after the company sold to Acitivs (ACT) which Carl Icahn continue to be a big supporter of the company.

Forest Laboratories and Adamas Pharmaceuticals Announce Forest’s Submission of New Drug Application for Memantine Extended Release and Donepezil Fixed-Dose Combination for Alzheimer’s Disease

Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, and Adamas Pharmaceuticals Inc., a privately held specialty pharmaceutical company, announced Forest’s submission of a New Drug Application (NDA) to the Food and Drug Administration for a fixed-dose combination (FDC) of memantine HCl extended release (ER) and donepezil HCl for the treatment of moderate to severe dementia of the Alzheimer’s type.

“The concurrent use of memantine and donepezil is a well-established treatment option for patients with moderate to severe dementia related to Alzheimer’s disease. Using the two drugs together appears to provide benefit over using acetylcholinesterase inhibitors alone. Reducing the number of pills by offering patients a fixed-dose combination helps lessen the daily medication burden and could improve patient adherence and compliance,” said Pierre Tariot, MD, at the Banner Alzheimer’s Institute, who has also consulted to both Adamas and Forest.

Alzheimer's Stocks to Watch - Here are some more potential alzheimers stocks to watch.  These companies have alzheimers drugs in the pipeline:  Targacept, Inc. (TRGT), Navidea Biopharmaceuticals, Inc (NAVB), Biogen Idec Inc. (BIIB), Transition Therapeutics Inc. (TTHI), Sangamo Biosciences Inc. (SGMO), Ligand Pharmaceuticals Incorporated (LGND), Prana Biotechnology (PRAN)

My Stock Forum
stockstobuy.org
Join Stockstobuy.org Today!